Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

ASCO 2014 roundup

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Comment: Advances in breast cancer presented at ASCO 2014

Upcoming trends in myeloma therapy

Lecture: Current use of systemic therapies in localised disease

Lecture: Current standard of care in advanced disease

Lecture: Exploring the androgen signalling pathway in CRPC

Personalisation of leukaemia treatment using genome sequencing